

1646  
Atty. Dkt. No. 089491-0201

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant:** Baumann et al.

**Title:** PROTECTION-OF-TELOMERE-1  
(POT-1) PROTEIN AND  
ENCODING POLYNUCLEOTIDES

**Appl. No.:** 09/816,248

**Filing  
Date:** 03/26/2001

**Examiner:**

**Art Unit:** 1646

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on the date below

\_\_\_\_\_  
(Printed Name)

\_\_\_\_\_  
(Signature)

\_\_\_\_\_  
(Date of Deposit)

**RECEIVED**

MAY 07 2003

TECH CENTER 1600/2900

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of a document known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed document is being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.113, or an action that otherwise closes prosecution in the application.

**RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

**STATEMENT**

The undersigned hereby states in accordance with 37 CFR §1.97(e)(1) that each item of information contained in this supplemental information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to filing of this Statement.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise

Atty. Dkt. No. 089491-0201

improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date \_\_\_\_\_

By \_\_\_\_\_

FOLEY & LARDNER

Customer Number: 30542



30542

PATENT TRADE-MARK OFFICE

Telephone: (858) 847-6767

Facsimile: (858) 792-6773

Richard J. Warburg  
Attorney for Applicant  
Registration No. 32,327

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Respond to a collection of information unless it contains a valid OMB control

Under the Paperwork Reduction Act of 1995, no persons are required to provide information to the IRS if the information is not necessary for the IRS to perform its functions. The IRS is not required to provide information to the IRS if the information is not necessary for the IRS to perform its functions. The IRS is not required to provide information to the IRS if the information is not necessary for the IRS to perform its functions.

**Complete if Known**

(use as many sheets as necessary)

Sheet 1 of 1

<b>Application Number</b>	09/816,248
<b>Filing Date</b>	03/26/2001
<b>First Named Inventor</b>	Peter Baumann
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	089491-0201

RECEIVED  
MAY 07 2003  
TECH CENTER 16

[illegible][illegible]

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A1	International Search Report dated April 15, 2003, issued for PCT Application No. PCT/US02/11107	
	A2	"ISOGA1 et al., "NEDO human cDNA sequencing project." Gene Sequence, February 22, 2000. NCB1 Database, National Center for Biotechnology Information, National Library of Medicine, NIH (Bethesda, MD, USA). Accession No. BAA91568.	

Examiner  
Signature

Date  
Considered

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible <sup>6</sup> Applicant is to place a check mark here if English language

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231